News Sentiment

VERA sentiment intelligence

Vera Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 38.50 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-8.3% over one week, +9.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA’s Accelerated FDA Approval - Learn Why

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -8.3% Price reacting lower
Trend fit Trend inactive 9.7% over four weeks
Fair value 19.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 39
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 11
simplywall.st 6
Sahm 5
Investing.com 5
MarketBeat 2
Simply Wall St. 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 29
Regulatory and legal 13
Earnings 9
Analyst action 4
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Market source Direct company coverage

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics announced inducement grants consisting of non-qualified stock options and restricted stock units to eight new employees. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires. The stock options and RSUs will

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:05
Source
Market source
Stock Titan Direct company coverage

New Vera Therapeutics employees receive $40.13 stock options in inducement plan

Vera Therapeutics announced that its Board Compensation Committee granted inducement equity awards to eight new employees on July 6, 2026. These awards include non-qualified stock options for 32,100 Class A shares with an exercise price of $40.13 and RSUs for 16,050 Class A share

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 19:39
Source
Stock Titan
Sahm Direct company coverage

Vera Therapeutics (VERA) Wins FDA Approval For TRUTAKNA, Is The Stock Fully Priced?

Vera Therapeutics (VERA) has received accelerated FDA approval for TRUTAKNA, its first commercial product for primary IgA nephropathy. Despite a year-to-date share price decline of 12.73%, the company has seen a 1-month rebound of 33.39% following the approval and a 74.25% one-ye

Tone
Positive 65/100
Event
Regulatory and legal
Published
10 Jul 2026 16:39
Source
Sahm
Investing.com Direct company coverage

Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million

Vera Therapeutics CEO Fordyce Marshall sold approximately $1.96 million worth of Class A Common Stock on July 7, 2026, under a pre-arranged trading plan. Despite the sale, the stock is considered undervalued by InvestingPro, and the company recently received FDA approval for its

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 22:43
Source
Investing.com
Stock Titan Direct company coverage

Vera Therapeutics (VERA) CEO preplanned sale of 46,250 shares reported

Vera Therapeutics CEO Marshall Fordyce reported the sale of 46,250 shares of Class A common stock on July 7, 2026, through a pre-planned trading arrangement (Rule 10b5-1(c)). The shares were sold at weighted-average prices between $40.39 and $43.97. Following these transactions,

Tone
Negative 31/100
Event
Market update
Published
09 Jul 2026 21:03
Source
Stock Titan
Quartr Direct company coverage

Vera Therapeutics (VERA) Proxy filing Summary

Vera Therapeutics (VERA) has scheduled its annual meeting for May 21, 2026, where shareholders will vote on the election of three Class II directors, the ratification of KPMG LLP as the 2026 auditor, and an advisory vote on executive compensation. Only Class A common stock holder

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 10:40
Source
Quartr
StocksToTrade Direct company coverage

VERA Stock Holds Gains As CEO Trims Stake In Form 4 Sale

Vera Therapeutics Inc. (NASDAQ: VERA) stock has risen by 9.52% due to positive clinical trial progress, despite its CEO, Marshall Fordyce, selling 18,500 shares for $701,769. Fordyce still retains a significant stake of over 420,000 shares, suggesting the sale is a profit-taking

Tone
Positive 67/100
Event
Deals and strategy
Published
07 Jul 2026 18:10
Source
StocksToTrade
Sahm Direct company coverage

What's Going on with Vera Therapeutics Stock on Monday?

Vera Therapeutics Inc. (NASDAQ: VERA) stock is gaining momentum as the company awaits a key FDA decision for its rare kidney disease drug, atacicept. The FDA's action date is July 7 for accelerated approval of atacicept for IgA Nephropathy, supported by positive data from the ORI

Tone
Neutral 50/100
Event
Regulatory and legal
Published
06 Jul 2026 22:39
Source
Sahm
TradingView Direct company coverage

Vera Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VERA)

This article provides key financial data and analyst insights for Vera Therapeutics, Inc. (NASDAQ:VERA). It covers the stock's recent performance, analyst price targets (ranging from $35.00 to $110.00), historical highs and lows, market capitalization, upcoming earnings reports,

Tone
Positive 72/100
Event
Earnings
Published
26 Jun 2026 03:09
Source
TradingView
Stock Titan Direct company coverage

Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan

Vera Therapeutics (VERA) CEO Marshall Fordyce sold a total of 18,500 shares of Class A Common Stock on June 23, 2026, under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share. Fo

Tone
Negative 29/100
Event
Market update
Published
25 Jun 2026 21:10
Source
Stock Titan
Investing.com Direct company coverage

Vera Therapeutics president and CEO Fordyce Marshall sells $701,769 in stock

Fordyce Marshall, President and CEO of Vera Therapeutics, sold 18,500 shares of company stock for over $700,000, executed under a pre-arranged trading plan. This sale follows a period of strong stock performance for Vera Therapeutics, which recently announced positive regulatory

Tone
Positive 67/100
Event
Regulatory and legal
Published
25 Jun 2026 05:10
Source
Investing.com